Medical Letter Questions 2

Question 1

TYPE 1 DIABETES LIR090
Two clinical trials in T1?

Will Novo go for T1 indication based on these trials?

Answer 1

ADJUCT ONE AND TWO

No. NN will look at results and decide how to proceed

Question 2

TYPE 1 DIABETES LIR090
In the randomized crossover of 45 patients with T1 by Pieber (15 each arm of 0.6, 1.2, and 1.8 mg each vs placebo):

What counter regulatory hormone was decreased in the hypo clamp?

Answer 2

Glucagon but not ss

Question 3

TYPE 1 DIABETES LIR090
In the randomized crossover of 45 patients with T1 by Pieber (~7 each arm of 0.6, 1.2, and 1.8 mg vs placebo):

How much more insulin dose decrease with Victoza 1.8?

Answer 3

~12 unit decrease not ss

Question 4

TYPE 1 DIABETES LIR090
In the randomized crossover of 45 patients with T1 by Pieber (~7 each arm of 0.6, 1.2, and 1.8 mg vs placebo):

How much more weight decrease with Victoza 1.8?

Answer 4

~6 lbs

Question 5

TYPE 1 DIABETES LIR090
Several investigator-sponsored studies have been conducted to evaluate the use of Victoza® in
patients with type 1 diabetes.

Overall, these studies have shown

a ________in A1C and body weight

a _______ or _______ in insulin dose and

__________ in hypoglycemia

Answer 5

Overall, these studies have shown:

a reduction in A1C and body weight

a reduction or no change in insulin dose

without an increase in hypoglycemia

Question 6

TYPE 2 DIABETES LIR156

Where should injection be made in relation to insulin?

Answer 6

Can be in same body region but not adjacent.